Janssen Inc. v. Canada (Health), 2023 FC 870
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Date | 17 July 2023 |
| Citation | 2023 FC 870 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
4 practice notes
-
2023 Year In Review: Life Sciences In Canada
...of non-obviousness and direct infringement of the 335 Patent's product claims. See the full decision here. Janssen Inc v. Canada (Health), 2023 FC 870: Judicial review of patent register eligibility: Is there a role for the "concurrent jurisdiction" category of In this case, the Federal Cou......
-
Federal Court Affirms OSIP Decision To Not List STELARA' On Patent Register
...Court in Janssen Inc. v. Canada (Health), 2023 FC 870 dismissed Janssen's application for judicial review of the decision of the Office of Submissions and Intellectual Property (OSIP) to not list Canadian Patent No. 3,113,837 (837 Patent) on the Patent Register. The 837 Patent relates to th......
-
Minister Of Health Reasonable In Deciding Patent For Janssen's STELARA Was Ineligible For Listing Against SNDSs
...with respect to two supplementary new drug submissions (SNDSs) for Janssen's STELARA (ustekinumab): Janssen Inc v Canada (Health), 2023 FC 870. Background Janssen filed two In February 2019, seeking approval for a new use of STELARA for the treatment of adult patients with moderately to sev......
-
Janssen Inc. v. Canada (Health), 2023 FCA 229
...224739 citing several reasons. Janssen sought judicial review of OSIP’s decision before the Federal Court, but this was dismissed (2023 FC 870, per Justice Mandy Aylen). For the purposes of the present appeal, it is sufficient to address only one of the reasons cited by OSIP: that th......
1 cases
-
Janssen Inc. v. Canada (Health), 2023 FCA 229
...224739 citing several reasons. Janssen sought judicial review of OSIP’s decision before the Federal Court, but this was dismissed (2023 FC 870, per Justice Mandy Aylen). For the purposes of the present appeal, it is sufficient to address only one of the reasons cited by OSIP: that th......
3 firm's commentaries
-
2023 Year In Review: Life Sciences In Canada
...of non-obviousness and direct infringement of the 335 Patent's product claims. See the full decision here. Janssen Inc v. Canada (Health), 2023 FC 870: Judicial review of patent register eligibility: Is there a role for the "concurrent jurisdiction" category of In this case, the Federal Cou......
-
Federal Court Affirms OSIP Decision To Not List STELARA' On Patent Register
...Court in Janssen Inc. v. Canada (Health), 2023 FC 870 dismissed Janssen's application for judicial review of the decision of the Office of Submissions and Intellectual Property (OSIP) to not list Canadian Patent No. 3,113,837 (837 Patent) on the Patent Register. The 837 Patent relates to th......
-
Minister Of Health Reasonable In Deciding Patent For Janssen's STELARA Was Ineligible For Listing Against SNDSs
...with respect to two supplementary new drug submissions (SNDSs) for Janssen's STELARA (ustekinumab): Janssen Inc v Canada (Health), 2023 FC 870. Background Janssen filed two In February 2019, seeking approval for a new use of STELARA for the treatment of adult patients with moderately to sev......